The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line
Erişim
info:eu-repo/semantics/openAccessTarih
2024Yazar
Tanriverdi, GamzeKaleci, Belisa
Yavuz, Furkan
Sahin, Hakan
Purelku, Merjem
Yazici, Zeliha
Kokturk, Sibel
Üst veri
Tüm öğe kaydını gösterKünye
Tanriverdi, G., Kaleci, B., Yavuz, F., Sahin, H., Purelku, M., Yazici, Z., & Kokturk, S. (2024). The effects of the combination of temozolomide and Eribulin on T98G human glioblastoma cell line: an ultrastructural study. Ultrastructural Pathology, 1-15.Özet
Glioblastoma tumors are the most aggressive primary brain tumors that develop resistance to temozolomide (TMZ). Eribulin (ERB) exhibits a unique mechanism of action by inhibiting microtubule dynamics during the G2/M cell cycle phase. We utilized the T98G human glioma cell line to investigate the effects of ERB and TMZ, both individually and in combination. The experimental groups were established as follows: control, E5 (5 nM ERB), T0.75 (0.75 mM TMZ), T1 (1.0 mM TMZ), and combination groups (E5+T0.75 and E5+T1). All groups showed a significant decrease in cell proliferation. Apoptotic markers revealed a time-dependent increase in annexin-V expression, across all treatment groups at the 48-hour time point. Caspase-3, exhibited an increase in the combination treatment groups at the 48-hour mark. Transmission electron microscopy (TEM) revealed normal ultrastructural features in the glioma cells of the control group. However, treatments induced ultrastructural changes within the spheroid glioblastoma model, particularly in the combination groups. These changes included a dose-dependent increase in autophagic vacuoles and apoptotic morphology of the cells. In conclusion, the similarity in the mechanism of action between ERB and TMZ suggests the potential for synergistic effects when combined. Our results highlight that this combination induced severe damage and autophagy in glioma spheroids after 48 hours.